FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307979506> ?p ?o ?g. }

• W4307979506 abstract "Abstract The usage of monoclonal antibodies (mAbs), as a matter associated with the biopharmaceutical industry, is increasingly growing. Harmonious with this concept, we designed the exquisitely modeled anti-MET scFv against breast cancer by gene cloning, and expression using a bacterial host. Herein, we developed a recombinant scFv against MET and examined its preclinical efficacy for the reduction of tumor growth, invasiveness and angiogenesis in vitro and in vivo. Expressed anti-MET scFv demonstrated high binding capacity (48.8%) toward MET-overexpressing cancer cells. The IC50 value of anti-MET scFv against MET-positive human breast cancer cell line (MDA-MB-435) was 11.4 nM whereas this value was measured as 47.01 nM in MET-negative cell line BT-483. Similar concentrations could also effectively induce apoptosis in MDA-MB-435 cancer cells. Moreover, this antibody fragment could reduce migration and invasion in MDA-MB-435 cells. Grafted breast tumors in Balb/c mice showed significant tumor growth suppression as well as reduction of blood-supply in response to recombinant anti-MET treatment. Histopathology and immunohistochemical assessments revealed higher rate of response to therapy. In our study, we designed and synthetized a novel anti-MET scFv which could effectively suppress MET-overexpressing breast cancer tumors." @default.
• W4307979506 created "2022-11-07" @default.
• W4307979506 creator A5002223984 @default.
• W4307979506 creator A5019205206 @default.
• W4307979506 creator A5020076589 @default.
• W4307979506 creator A5021425419 @default.
• W4307979506 creator A5026890794 @default.
• W4307979506 creator A5053093848 @default.
• W4307979506 creator A5057724942 @default.
• W4307979506 creator A5059913621 @default.
• W4307979506 creator A5060987630 @default.
• W4307979506 creator A5077440950 @default.
• W4307979506 creator A5082697212 @default.
• W4307979506 date "2022-11-02" @default.
• W4307979506 modified "2023-10-18" @default.
• W4307979506 title "Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer" @default.
• W4307979506 cites W1829282773 @default.
• W4307979506 cites W1837507354 @default.
• W4307979506 cites W1900281816 @default.
• W4307979506 cites W1977889545 @default.
• W4307979506 cites W1981214889 @default.
• W4307979506 cites W1983257260 @default.
• W4307979506 cites W1993575340 @default.
• W4307979506 cites W1995081934 @default.
• W4307979506 cites W2014158928 @default.
• W4307979506 cites W2017081079 @default.
• W4307979506 cites W2020304503 @default.
• W4307979506 cites W2024071947 @default.
• W4307979506 cites W2027684043 @default.
• W4307979506 cites W2041488627 @default.
• W4307979506 cites W2045401427 @default.
• W4307979506 cites W2052181418 @default.
• W4307979506 cites W2054633892 @default.
• W4307979506 cites W2059992550 @default.
• W4307979506 cites W2069421644 @default.
• W4307979506 cites W2092064654 @default.
• W4307979506 cites W2094337993 @default.
• W4307979506 cites W2101574075 @default.
• W4307979506 cites W2106688644 @default.
• W4307979506 cites W2131619253 @default.
• W4307979506 cites W2138896702 @default.
• W4307979506 cites W2142857044 @default.
• W4307979506 cites W2166015942 @default.
• W4307979506 cites W2280504235 @default.
• W4307979506 cites W2295455218 @default.
• W4307979506 cites W2339824543 @default.
• W4307979506 cites W2415521731 @default.
• W4307979506 cites W2494710035 @default.
• W4307979506 cites W2529172551 @default.
• W4307979506 cites W2531906150 @default.
• W4307979506 cites W2571138221 @default.
• W4307979506 cites W2577900529 @default.
• W4307979506 cites W2750691704 @default.
• W4307979506 cites W2795063553 @default.
• W4307979506 cites W2795945766 @default.
• W4307979506 cites W2802552316 @default.
• W4307979506 cites W2898197409 @default.
• W4307979506 cites W2898247719 @default.
• W4307979506 cites W2900826672 @default.
• W4307979506 cites W2936978491 @default.
• W4307979506 cites W3182298817 @default.
• W4307979506 cites W4200068588 @default.
• W4307979506 cites W4205502918 @default.
• W4307979506 cites W4292296525 @default.
• W4307979506 doi "https://doi.org/10.21203/rs.3.rs-2216162/v1" @default.
• W4307979506 hasPublicationYear "2022" @default.
• W4307979506 type Work @default.
• W4307979506 citedByCount "0" @default.
• W4307979506 crossrefType "posted-content" @default.
• W4307979506 hasAuthorship W4307979506A5002223984 @default.
• W4307979506 hasAuthorship W4307979506A5019205206 @default.
• W4307979506 hasAuthorship W4307979506A5020076589 @default.
• W4307979506 hasAuthorship W4307979506A5021425419 @default.
• W4307979506 hasAuthorship W4307979506A5026890794 @default.
• W4307979506 hasAuthorship W4307979506A5053093848 @default.
• W4307979506 hasAuthorship W4307979506A5057724942 @default.
• W4307979506 hasAuthorship W4307979506A5059913621 @default.
• W4307979506 hasAuthorship W4307979506A5060987630 @default.
• W4307979506 hasAuthorship W4307979506A5077440950 @default.
• W4307979506 hasAuthorship W4307979506A5082697212 @default.
• W4307979506 hasBestOaLocation W43079795061 @default.
• W4307979506 hasConcept C104317684 @default.
• W4307979506 hasConcept C121608353 @default.
• W4307979506 hasConcept C126322002 @default.
• W4307979506 hasConcept C150903083 @default.
• W4307979506 hasConcept C159654299 @default.
• W4307979506 hasConcept C203014093 @default.
• W4307979506 hasConcept C204232928 @default.
• W4307979506 hasConcept C207001950 @default.
• W4307979506 hasConcept C2780394083 @default.
• W4307979506 hasConcept C2781018059 @default.
• W4307979506 hasConcept C2781230642 @default.
• W4307979506 hasConcept C29537977 @default.
• W4307979506 hasConcept C40767141 @default.
• W4307979506 hasConcept C502942594 @default.
• W4307979506 hasConcept C530470458 @default.
• W4307979506 hasConcept C542903549 @default.
• W4307979506 hasConcept C55493867 @default.
• W4307979506 hasConcept C71924100 @default.
• W4307979506 hasConcept C86803240 @default.

• next